IDSA GUIDELINES Bundle (free trial)

Pediatric Community-Acquired Pneumonia

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/63099

Contents of this Issue

Navigation

Page 18 of 25

Dosing Recommendations Prophylaxisb Children Adults 75 mg once daily ≤ 15 kg 30 mg once daily > 15-23 kg 45 mg once daily > 23-40 kg 60 mg once daily > 40 kg 75 mg once daily For prophylaxis of infants < 24 mo of age: 9-23 mo: 3.5 mg/kg once daily 3-8 mo: 3 mg/kg once daily NOT routinely recommended for infants < 3 mo of age due to limited data in this age group Children ≥ 5 y and Adults 2 inhalations (10 mg total per dose), once daily for 10 days Adamantane-Based Drugs (not currently used due to resistance) 1-9 y 9-12 y Same as treatment dose Same as treatment dose Same as treatment dose 1-9 y 5 mg/kg once daily, not to exceed 150 mgc ≥ 10 y 200 mg/day, either as a single daily dose or div bid 200 mg/day, either as a single daily dose or div bid b In children for whom prophylaxis is indicated, antiviral drugs should be continued for the duration of known influenza activity in the community because of the potential for repeated and unknown exposures, or until immunity can be achieved aſter immunization. c FDA approved for prophylaxis down to 12 mo of age. 17

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Pediatric Community-Acquired Pneumonia